{"id":1231,"date":"2026-10-26T05:27:00","date_gmt":"2026-10-26T09:27:00","guid":{"rendered":"https:\/\/drugchatter.com\/insights\/?p=1231"},"modified":"2026-09-21T23:16:57","modified_gmt":"2026-09-22T03:16:57","slug":"off-label-revenue-is-real-revenue-its-also-fragile-revenue","status":"publish","type":"post","link":"https:\/\/drugchatter.com\/insights\/off-label-revenue-is-real-revenue-its-also-fragile-revenue\/","title":{"rendered":"Off-Label Revenue Is Real Revenue. It’s Also Fragile Revenue."},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

In April 2018, the Department of Justice intervened in five whistleblower lawsuits against Insys Therapeutics, alleging the company had built its fentanyl spray business by pushing the drug into patients who did not have the cancer diagnosis its label required [1]. Fourteen months later, a federal jury convicted Insys founder John Kapoor and four other executives of racketeering conspiracy. Within weeks, Insys filed for Chapter 11 bankruptcy [2]. A drug approved for a narrow population generated a company-defining revenue stream by reaching a much larger one, and then that revenue stream ended the company.<\/p>\n\n\n\n

Off-label prescribing is legal, common, and often clinically necessary. It is also, for the manufacturer sitting behind it, one of the least durable revenue categories in the industry. This piece maps five distinct ways off-label revenue breaks, using five real, verifiable cases: a criminal prosecution, a $3 billion fraud settlement, a warning-label reversal, a shortage-driven compounding boom that ended by regulatory calendar, and a First Amendment fight that resolved into an on-label approval. Each case shows a different failure mode. None of them was priced into anyone’s forecast when the revenue was still growing.<\/p>\n\n\n\n

The Short Answer<\/h2>\n\n\n\n

Off-label use generates measurable, sometimes substantial, revenue for approved drugs. That revenue sits outside the label’s legal protection for manufacturer promotion, outside payer coverage guarantees, outside the evidentiary basis the FDA used to approve the product, and often outside any compendia-based reimbursement rule. Any one of those gaps can close on a timeline the manufacturer does not control: a Department of Justice settlement, a black-box warning, an expired shortage listing, a changed clinical guideline, or a payer coverage decision. Five real cases below show each mechanism at work.<\/p>\n\n\n\n

What “Off-Label Revenue” Actually Means<\/h2>\n\n\n\n

The Legal Distinction Between Off-Label Use and Off-Label Promotion<\/h3>\n\n\n\n

A drug’s FDA label lists the indications, populations, and dosing the agency reviewed and approved. Physicians may prescribe an approved drug for any use once it is on the market; the Food, Drug, and Cosmetic Act does not restrict prescribing discretion [3]. What the FDCA has restricted, through its misbranding provisions, is manufacturer promotion of uses the label does not cover. That distinction, prescribing versus promoting, is the hinge the entire off-label revenue question turns on.<\/p>\n\n\n\n

Why Manufacturers Can’t Just Advertise What Works<\/h3>\n\n\n\n

A drug marketed for a use its label does not address is considered to lack adequate directions for safe use, which makes it misbranded under 21 C.F.R. \u00a7\u00a7 201.5 and 201.128 [4]. Historically, that has been a criminal offense. It is also the legal theory behind nearly every major off-label settlement of the past two decades, from Pfizer’s 2009 Bextra resolution to GlaxoSmithKline’s 2012 case, discussed below.<\/p>\n\n\n\n

Key Figures<\/h4>\n\n\n\n

Off-label prescribing prevalence estimates vary widely by data source, drug class, and study period, generally landing somewhere between roughly one in ten and nearly one in three prescriptions depending on methodology. The revenue exposure that follows from that prevalence is concentrated: it clusters in psychiatry, oncology, and hormone therapy far more than in categories with narrow, well-defined labels.<\/p>\n\n\n\n

Five Ways Off-Label Revenue Breaks<\/h2>\n\n\n\n

Off-label revenue does not fail for one reason. Across the cases examined for this piece, five distinct mechanisms recur, and they are not mutually exclusive; a single drug can face more than one at once.<\/p>\n\n\n\n

Enforcement Risk: When Promotion Crosses Into Misbranding<\/h3>\n\n\n\n

The Department of Justice and FDA pursue False Claims Act and misbranding actions against companies whose sales conduct, not merely their doctors’ prescribing, drove off-label use. This is the oldest and most litigated failure mode, and it produced the largest healthcare fraud settlement in U.S. history in 2012 [5].<\/p>\n\n\n\n

Example<\/h4>\n\n\n\n

Insys Therapeutics and GlaxoSmithKline, both detailed below.<\/p>\n\n\n\n

Evidence Risk: When New Trial Data Reverses the Rationale<\/h3>\n\n\n\n

Off-label prescribing frequently rests on smaller studies, case series, or extrapolated mechanism of action rather than a randomized trial in the specific population being treated. When a large outcomes trial finally runs, in either direction, the prescribing rationale can collapse or, less commonly, convert into an approved indication.<\/p>\n\n\n\n

Example<\/h4>\n\n\n\n

AndroGel’s boxed warning reversal after the TRAVERSE trial, and Vascepa’s approval after REDUCE-IT, both below.<\/p>\n\n\n\n

Regulatory-Tolerance Risk: When a Temporary Allowance Expires<\/h3>\n\n\n\n

Some revenue is not built on off-label promotion at all but on a legal gray zone that exists only under specific, time-limited conditions, such as a federal drug shortage listing that permits large-scale compounding of a copy of an approved product. When the underlying condition ends, so does the legal basis for the revenue, on a date the manufacturer of the copy does not set.<\/p>\n\n\n\n

Example<\/h4>\n\n\n\n

Compounded semaglutide and tirzepatide, below.<\/p>\n\n\n\n

Guideline and Compendia Risk: When Third-Party Support Disappears<\/h3>\n\n\n\n

Government and commercial payers frequently defer off-label coverage decisions to recognized compendia (in oncology, for example, the National Comprehensive Cancer Network) or to clinical practice guidelines from medical societies. When a compendium removes a listing or a society revises guidance, the coverage basis for that off-label use can disappear even though the drug itself, and physicians’ legal ability to prescribe it, has not changed.<\/p>\n\n\n\n

Example<\/h4>\n\n\n\n

Antipsychotic prescribing for dementia-related agitation lost guideline support and roughly a fifth of its volume after FDA’s 2005 black box warning, a case examined at length in DrugChatter’s earlier forecasting analysis of off-label demand.<\/p>\n\n\n\n

Reimbursement Risk: When Payers Simply Stop Paying<\/h3>\n\n\n\n

Even where prescribing remains legal and clinically defensible, commercial and government payers can deny coverage for a use outside the label, shifting the cost to the patient and collapsing volume without any FDA or DOJ action at all. This is the least visible failure mode because it produces no press release, only a demand curve that bends.<\/p>\n\n\n\n

Example<\/h4>\n\n\n\n

Off-label weight-loss prescribing of GLP-1 drugs, where most commercial plans exclude coverage for the indication regardless of the compounding question discussed below.<\/p>\n\n\n\n

Type<\/th>Trigger<\/th>Who acts<\/th>Case study below<\/th><\/tr><\/thead>
Enforcement<\/td>DOJ\/FDA finds promotion crossed into misbranding or kickbacks<\/td>Federal prosecutors<\/td>Insys, GSK<\/td><\/tr>
Evidence<\/td>Large trial confirms or reverses the off-label rationale<\/td>Trial sponsors, FDA<\/td>AndroGel, Vascepa<\/td><\/tr>
Regulatory tolerance<\/td>A shortage listing or enforcement discretion window ends<\/td>FDA<\/td>Compounded semaglutide<\/td><\/tr>
Guideline\/compendia<\/td>A recognized compendium or society revises support for the use<\/td>Medical societies, CMS-recognized compendia<\/td>Antipsychotics in dementia (prior DrugChatter analysis)<\/td><\/tr>
Reimbursement<\/td>Payers exclude the indication from coverage<\/td>Commercial and government payers<\/td>GLP-1 weight-loss coverage<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Case Study: Insys Therapeutics and the Subsys Speaker Program<\/h2>\n\n\n\n

A Cancer Drug Sold Mostly to Non-Cancer Patients<\/h3>\n\n\n\n

Subsys, a sublingual fentanyl spray, was approved in 2012 for breakthrough pain in cancer patients already tolerant to opioids, a narrow and comparatively small population [6]. According to a former national sales director’s later court testimony, the company’s internal culture treated on-label and off-label prescribing as functionally interchangeable: “no one at the company cared whether the doctors were prescribing it on-label for cancer patients or off-label for anyone else” [6]. Insys built a speaker program, ostensibly for physician education, that prosecutors said functioned as a bribery mechanism to reward high-volume, largely non-oncology prescribers [7].<\/p>\n\n\n\n

The Mechanics of the Kickback Scheme<\/h3>\n\n\n\n

Prosecutors described a daily internal call, referred to as the “8:30 call,” where Kapoor and other executives tracked prescriber return on investment, comparing the net revenue generated by targeted physicians against the value of bribes paid to them, and removing underperforming prescribers from the speaker program [7]. Insys sales staff also allegedly misrepresented patient diagnoses to insurers to secure reimbursement for prescriptions that would not otherwise have been covered [2].<\/p>\n\n\n\n

Key Figures<\/h4>\n\n\n\n

In May 2019, a federal jury convicted Kapoor and four co-defendants of racketeering conspiracy after 15 days of deliberation [8]. Kapoor was sentenced in January 2020 to 66 months in prison and a $250,000 fine [7]. Insys agreed to pay $225 million to resolve criminal and civil liability [2], and the company filed for Chapter 11 bankruptcy within days of that settlement [2]. As recently as September 2025, the U.S. Attorney’s Office in Massachusetts reported it had collected $48 million in court-ordered restitution from the convicted executives, a reminder that enforcement consequences from off-label-driven revenue can extend years past the settlement date [9].<\/p>\n\n\n\n

Case Study: GlaxoSmithKline’s $3 Billion Off-Label Settlement<\/h2>\n\n\n\n

Paxil in Children, Wellbutrin for Everything Else<\/h3>\n\n\n\n

GSK’s case, resolved in July 2012, remains the largest healthcare fraud settlement in U.S. history [10]. The Department of Justice alleged that between April 1998 and August 2003, GSK promoted the antidepressant Paxil for treating depression in patients under 18, an unapproved use, despite three clinical studies that failed to establish its effectiveness in that population [11]. Separately, from January 1999 to December 2003, GSK promoted Wellbutrin, approved only for major depressive disorder in adults, for weight loss, sexual dysfunction, substance addiction, and attention-deficit hyperactivity disorder [11].<\/p>\n\n\n\n

What the Settlement Actually Covered<\/h3>\n\n\n\n

GSK pleaded guilty to a three-count criminal information, including two counts of introducing misbranded drugs into interstate commerce [12]. The civil resolution additionally covered off-label promotion of Advair, Lamictal, and Zofran, alongside kickbacks tied to Imitrex, Lotronex, Flovent, and Valtrex, plus GSK’s separate failure to report cardiovascular safety data on its diabetes drug Avandia to FDA [12].<\/p>\n\n\n\n

Key Figures<\/h4>\n\n\n\n

The $3 billion total broke down into roughly $1 billion in criminal fines and forfeitures and about $2 billion in civil False Claims Act liability, including $300 million tied to underpaid Medicaid rebates [13][10]. The case originated with a 2003 whistleblower complaint from two former GSK sales representatives, Greg Thorpe and Blair Hamrick, and the federal government did not intervene until January 2011, nearly eight years later [14].<\/p>\n\n\n\n

Company\/Drug<\/th>Year<\/th>Amount<\/th>Core allegation<\/th><\/tr><\/thead>
GlaxoSmithKline (Paxil, Wellbutrin, others)<\/td>2012<\/td>$3.0 billion<\/td>Off-label promotion, kickbacks, safety non-disclosure<\/td><\/tr>
Purdue Pharma (OxyContin, misbranding)<\/td>2007<\/td>$634.5 million<\/td>Misrepresenting abuse and addiction risk<\/td><\/tr>
Elan\/Eisai (Zonegran)<\/td>2010<\/td>$214.5 million<\/td>Off-label promotion for uses not medically accepted<\/td><\/tr>
Johnson & Johnson subsidiaries (Topamax)<\/td>2010<\/td>$81.3 million<\/td>Off-label psychiatric promotion<\/td><\/tr>
Shire (Adderall XR, Vyvanse, others)<\/td>2014<\/td>$56.5 million<\/td>Off-label promotion, unsupported efficacy claims<\/td><\/tr>
Insys Therapeutics (Subsys)<\/td>2019<\/td>$225 million<\/td>Off-label promotion via kickback-funded speaker program<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Case Study: AndroGel and the Testosterone Boom, Bust, and Rebound<\/h2>\n\n\n\n

A $2.3 Billion Market Built on Expanding “Low T”<\/h3>\n\n\n\n

By 2013, the U.S. testosterone replacement therapy market had grown to roughly $2.3 billion in annual sales, with AndroGel, marketed first by Solvay and then by Abbott\/AbbVie, holding the leading share [15]. AndroGel’s approved indication covers men with diagnosed hypogonadism, a condition confirmed by lab testing, not the general age-related decline in testosterone that direct-to-consumer marketing associated with fatigue and low libido [16]. Litigation later alleged that AbbVie sales representatives encouraged physicians to screen men seeking Viagra prescriptions for low testosterone, effectively using an approved erectile-dysfunction drug as a referral channel for an off-label AndroGel market [16]. AndroGel’s own annual U.S. sales peaked at roughly $600 million around this period [17].<\/p>\n\n\n\n

The Warning That Cut Prescribing Nearly in Half<\/h3>\n\n\n\n

FDA issued a Drug Safety Communication in January 2014 flagging reported cardiovascular risks, followed by a September 2014 advisory committee meeting and a March 2015 label change requiring a boxed warning about possible increased risk of heart attack and stroke, alongside explicit language that testosterone products were not approved for age-related low testosterone [18]. One widely cited study found testosterone prescriptions fell 48 percent among established users and 62 percent among new users between 2013 and 2016 [19]. A separate 2021 JAMA Network Open study of nearly 45 million Medicare Advantage and commercial-insurance patient-quarters found receipt among men without cardiovascular disease fell from about 28 percent in 2011 to just under 20 percent by 2018, roughly a one-third decline [20].<\/p>\n\n\n\n

TRAVERSE, February 2025, and the Reversal Nobody Had Modeled<\/h3>\n\n\n\n

In 2023, the industry-wide TRAVERSE cardiovascular outcomes trial, which FDA had itself requested after the 2014 advisory committee meeting, found no increased risk of major adverse cardiac events among hypogonadal men on testosterone therapy [21]. On that basis, FDA removed the boxed cardiovascular warning from all testosterone products in February 2025 [21]. Epic Research data released in July 2026 shows testosterone prescribing, which fell from a 0.83 percent share of male patients in 2013 to 0.64 percent in 2021, has since risen to 0.93 percent in 2025 and 0.95 percent in the first half of 2026, with every age group above 30 now exceeding its early-2010s peak [21].<\/p>\n\n\n\n

Key Figures<\/h4>\n\n\n\n
Year<\/th>Share<\/th>Regulatory context<\/th><\/tr><\/thead>
2013<\/td>0.83%<\/td>Pre-warning peak<\/td><\/tr>
2021<\/td>0.64%<\/td>Post-2015 boxed warning trough<\/td><\/tr>
2025<\/td>0.93%<\/td>After February 2025 warning removal<\/td><\/tr>
H1 2026<\/td>0.95%<\/td>Continued rebound<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Source: Epic Research, July 2026 [21].<\/p>\n\n\n\n

Case Study: Compounded Semaglutide and the GLP-1 Off-Ramp<\/h2>\n\n\n\n

How a Shortage Created a Parallel Market<\/h3>\n\n\n\n

Federal law permits state-licensed 503A pharmacies and FDA-registered 503B outsourcing facilities to compound a copy of an approved drug while that drug sits on FDA’s official shortage list. Wegovy entered the shortage list in March 2022 and Ozempic in August 2022, and demand for GLP-1 receptor agonists far outpaced Novo Nordisk’s manufacturing capacity for years afterward [22]. Compounded versions typically sold for roughly $150 to $300 per month, against list prices exceeding $1,000 for the branded products, and an entire telehealth and medical-spa industry scaled around that price gap [23].<\/p>\n\n\n\n

February 21, 2025: The Day the Legal Basis Ended<\/h3>\n\n\n\n

FDA determined the tirzepatide shortage resolved in October 2024 and the semaglutide shortage resolved on February 21, 2025 [24][25]. Under the enforcement discretion FDA extended to avoid abrupt disruption, 503A pharmacies could continue compounding semaglutide only until April 22, 2025, and 503B outsourcing facilities only until May 22, 2025 [24]. The Outsourcing Facilities Association sued FDA over both determinations; courts denied preliminary injunctions in each case, and the enforcement deadlines held [23].<\/p>\n\n\n\n

What Happened to the Revenue Built on the Gap<\/h3>\n\n\n\n

Novo Nordisk filed numerous lawsuits against medical spas, weight-loss clinics, and pharmacies it alleged were unlawfully marketing and selling compounded products as “semaglutide” [26]. Hims & Hers said it would stop selling commercially available doses of compounded semaglutide by the end of FDA’s wind-down window, while continuing to offer personalized dosing regimens under a narrower exception, and still projected roughly $2.4 billion in 2025 revenue from its broader business [27]. In April 2026, FDA went further, proposing to permanently remove semaglutide, tirzepatide, and liraglutide from the list of substances 503B facilities may compound in bulk, issuing 30 warning letters to compounding operations, and opening a public comment period running through June 29, 2026 [28].<\/p>\n\n\n\n

Key Figures<\/h4>\n\n\n\n

Compounded GLP-1 pricing ran at roughly 15 to 30 percent of branded list price during the shortage window [23]. Tirzepatide’s shortage status has proven less stable than semaglutide’s, returning briefly to the shortage list in 2025 after its October 2024 resolution, illustrating that even the regulatory trigger itself can be less predictable than manufacturers of copies assume [29].<\/p>\n\n\n\n

Case Study: Vascepa and the Off-Label Fight That Ended in Approval<\/h2>\n\n\n\n

A Narrow Label and a Bigger Population Next Door<\/h3>\n\n\n\n

FDA approved Vascepa (icosapent ethyl) in July 2012 as an adjunct to diet for adults with severe hypertriglyceridemia, triglyceride levels of 500 mg\/dL or higher, a relatively small population [30]. Amarin sought a broader indication covering patients with triglycerides between 200 and 499 mg\/dL who remained on statin therapy, a much larger commercial opportunity, but FDA denied that supplemental application and warned that marketing Vascepa to the broader group without approval would render it misbranded [30].<\/p>\n\n\n\n

Caronia, Amarin, and the First Amendment Argument<\/h3>\n\n\n\n

Amarin sued, leaning on the Second Circuit’s 2012 ruling in United States v. Caronia, which had vacated the misbranding conviction of a sales representative for Xyrem-maker Orphan Medical on First Amendment grounds, holding that truthful, non-misleading off-label promotional speech cannot alone support a misbranding prosecution [31]. In August 2015, the U.S. District Court for the Southern District of New York granted Amarin a preliminary injunction, ruling it could make specific, truthful, non-misleading statements about Vascepa’s potential benefit for patients with persistently high triglycerides [32]. FDA settled in March 2016 rather than appeal, formally conceding the principle and giving Amarin a process to seek pre-clearance for up to two additional off-label communications per year through 2020 [33].<\/p>\n\n\n\n

REDUCE-IT and the December 2019 Conversion to On-Label Revenue<\/h3>\n\n\n\n

Rather than relying solely on the First Amendment win, Amarin completed REDUCE-IT, a cardiovascular outcomes trial, reporting topline results in September 2018 [34]. FDA’s advisory committee voted 16 to 0 in November 2019 to recommend approval, and on December 13, 2019, FDA approved an expanded label covering the reduction of cardiovascular events in statin-treated patients with elevated triglycerides and established cardiovascular disease or diabetes [34]. The trial showed a 30 percent relative reduction in major adverse cardiac events over five years, equivalent to one fewer event per six patients treated [35]. Amarin raised its 2019 revenue guidance to $410 million to $425 million and projected $650 million to $700 million for 2020, both materially above pre-approval levels [35].<\/p>\n\n\n\n

Key Figures<\/h4>\n\n\n\n

Vascepa is the only case in this piece where off-label revenue exposure resolved by converting into an approved indication rather than collapsing, underscoring that the evidence-risk mechanism described earlier in this piece can run in either direction.<\/p>\n\n\n\n

What Changed in the Legal Landscape<\/h2>\n\n\n\n

The Post-Caronia Enforcement Data<\/h3>\n\n\n\n

Caronia did not end off-label enforcement. A 2021 study in the Journal of Health Politics, Policy and Law reviewed 42 federal cases citing Caronia between 2012 and 2019 and found courts split almost evenly: 22 cases, 52 percent, followed its core holding that truthful off-label promotion is not independently actionable, while 20 cases, 48 percent, either declined to follow it or distinguished it on the facts [36]. The Department of Justice publicly stated it did not believe Caronia would significantly change its enforcement of the FDCA’s misbranding provisions, and subsequent prosecutors have generally shifted toward cases built on “plus factors,” such as kickbacks or misleading claims, rather than pure truthful-speech theories [37].<\/p>\n\n\n\n

FDA’s Final SIUU Guidance<\/h3>\n\n\n\n

FDA finalized its guidance on Scientific Information on Unapproved Uses (SIUU) communications on January 6, 2025, replacing a 2014 predecessor and finalizing an October 2023 draft [38]. The guidance describes conditions under which a firm’s proactive, unsolicited scientific communication about an unapproved use, provided it is truthful, non-misleading, drawn from scientifically sound sources, and accompanied by disclosure of study limitations and contrary findings, will not by itself be treated as evidence of a new intended use [39]. As of its finalization, the guidance remained subject to Office of Management and Budget review of its information-collection provisions before implementation [40].<\/p>\n\n\n\n

Why Enforcement Discretion Is Not a Legal Safe Harbor<\/h3>\n\n\n\n

SIUU guidance describes FDA’s own enforcement discretion policy; it does not amend the FDCA’s misbranding statute, and it explicitly does not extend to communications about investigational compounds unapproved for any use, or to off-label communications aimed at patients rather than health care providers [39]. A company that satisfies the SIUU framework reduces its exposure to an FDA intended-use finding. It does not eliminate exposure to a False Claims Act theory built on reimbursement fraud, kickbacks, or misleading claims, the theories underlying every settlement in the table above.<\/p>\n\n\n\n

\n

“On-label and off-label testosterone therapy declined following the [2014 FDA] safety communication. Certain physician characteristics were associated with changes in off-label, but not on-label, prescribing.” [41]<\/p>\n<\/blockquote>\n\n\n\n

What This Means for Pharma Teams<\/h2>\n\n\n\n

For Commercial and Brand Forecasting<\/h3>\n\n\n\n

A revenue forecast that includes off-label volume without tagging which of the five fragility types applies is incomplete. Enforcement risk and regulatory-tolerance risk can eliminate volume within a single fiscal quarter, as the GLP-1 compounding wind-down and the Insys bankruptcy both show. Evidence risk can move in either direction, so it deserves separate scenario planning rather than a flat haircut.<\/p>\n\n\n\n

For Medical Affairs<\/h3>\n\n\n\n

SIUU communications occupy a narrow, well-defined lane: unsolicited, HCP-directed, evidence-disclosed, and truthful. Medical affairs teams responding to unsolicited HCP requests operate under a different and generally more permissive framework than SIUU communications, and conflating the two is a recurring source of internal confusion documented across the enforcement history above.<\/p>\n\n\n\n

For Legal and Compliance<\/h3>\n\n\n\n

The 48 percent of post-Caronia cases that declined to extend its holding is a reminder that a favorable ruling in one circuit, or even a settlement as sweeping as Amarin’s, does not generalize automatically. Every case examined in this piece that ended in a settlement rather than a First Amendment win involved kickbacks, false reimbursement claims, or misleading efficacy statements, not merely truthful off-label speech.<\/p>\n\n\n\n

For Market Access<\/h3>\n\n\n\n

Reimbursement risk is the quietest of the five mechanisms because it produces no headline. A payer coverage exclusion for an off-label indication, common for GLP-1 weight-loss use regardless of the compounding question, can flatten volume growth with no enforcement action, no trial readout, and no shortage-list change at all.<\/p>\n\n\n\n

Where AI Answers Fit Into the Fragility Picture<\/h2>\n\n\n\n

Large-language-model chatbots increasingly answer patient and clinician questions about drug safety and off-label use, and several of the reversals documented in this piece happened fast enough to outrun a model’s training data. A model trained before February 2025 will still describe a boxed cardiovascular warning on testosterone products that FDA has since removed; a model trained before the semaglutide shortage was declared resolved may still describe compounded GLP-1s as a routine, broadly available option. DrugChatter’s AI-monitoring methodology exists specifically to catch this kind of drift between what a model says and what the current label, shortage status, or guidance document actually states, rather than to substitute for either.<\/p>\n\n\n\n

Frequently Asked Questions<\/h2>\n\n\n\n

Is it illegal for a doctor to prescribe a drug off-label?<\/h3>\n\n\n\n

No. Physicians may lawfully prescribe an FDA-approved drug for any use, dose, or patient population once it is on the market. The FDCA restricts manufacturer promotion of unapproved uses, not physician prescribing discretion [3].<\/p>\n\n\n\n

What is the difference between off-label use and off-label promotion?<\/h3>\n\n\n\n

Off-label use is a prescribing decision made by a physician; off-label promotion is a marketing decision made by a manufacturer. Court rulings since 2012 have narrowed the FDCA’s restriction on the latter for truthful, non-misleading speech, but have not touched the former [31].<\/p>\n\n\n\n

Did the courts make off-label promotion legal?<\/h3>\n\n\n\n

Not entirely. Caronia and Amarin established First Amendment protection for truthful, non-misleading off-label speech, but a 2021 academic review found federal courts split almost evenly on how far to extend that protection, and enforcement built on kickbacks, false claims, or misleading statements continues [36].<\/p>\n\n\n\n

What is FDA’s SIUU guidance?<\/h3>\n\n\n\n

SIUU stands for Scientific Information on Unapproved Uses. FDA finalized this guidance on January 6, 2025, describing when a firm’s proactive scientific communication about an unapproved use will not, by itself, be treated as evidence of a new intended use. It is an enforcement discretion policy, not a change to the underlying misbranding statute [38][39].<\/p>\n\n\n\n

How big is off-label prescribing as a share of the market?<\/h3>\n\n\n\n

Estimates vary widely by data source, drug class, and study period, generally landing somewhere between roughly one in ten and nearly one in three prescriptions, with much higher concentrations in categories such as pediatric psychiatry, oncology, and hormone therapy.<\/p>\n\n\n\n

Why did Insys Therapeutics go bankrupt?<\/h3>\n\n\n\n

Insys built most of its Subsys revenue on off-label prescribing reinforced by a kickback-funded speaker program. A 2019 racketeering conviction of its founder and four executives, a $225 million settlement, and a Chapter 11 filing followed within weeks of each other [2][7].<\/p>\n\n\n\n

What happened to testosterone therapy sales after the FDA’s 2015 warning?<\/h3>\n\n\n\n

Prescribing fell roughly 48 percent among established users and 62 percent among new users between 2013 and 2016 [19]. FDA removed the boxed cardiovascular warning in February 2025 after the TRAVERSE trial found no increased risk, and prescribing has since risen past its early-2010s peak [21].<\/p>\n\n\n\n

Why did the FDA restrict compounded semaglutide?<\/h3>\n\n\n\n

Compounding a copy of an approved drug is legal only while that drug is officially listed in shortage. FDA declared the semaglutide shortage resolved on February 21, 2025, ending the legal basis for mass compounding after phased wind-down deadlines [24][25].<\/p>\n\n\n\n

Can a company promote a drug for an off-label use if it has strong clinical data?<\/h3>\n\n\n\n

Strong data narrows legal risk but does not eliminate it. SIUU guidance permits truthful, adequately disclosed scientific communications, but claims that exceed the data, omit contrary findings, or target reimbursement decisions remain enforcement targets [39].<\/p>\n\n\n\n

What eventually happened with Amarin’s Vascepa off-label dispute?<\/h3>\n\n\n\n

Amarin settled its First Amendment suit against FDA in 2016, then completed the REDUCE-IT trial. FDA approved an expanded, on-label indication covering that use in December 2019, converting the disputed off-label revenue into higher-guided, on-label revenue [30][34][35].<\/p>\n\n\n\n

Key Takeaways<\/h2>\n\n\n\n
    \n
  • Off-label revenue fails through five distinct mechanisms, not one: enforcement action, reversed clinical evidence, expired regulatory tolerance, lost guideline or compendia support, and withdrawn payer reimbursement.<\/li>\n\n\n\n
  • Insys Therapeutics’ Subsys revenue, built substantially on off-label, kickback-driven prescribing, ended in a 2019 racketeering conviction, a $225 million settlement, and bankruptcy within the same year [2][7].<\/li>\n\n\n\n
  • GlaxoSmithKline’s $3 billion 2012 settlement remains the largest healthcare fraud resolution in U.S. history and covered off-label promotion of at least five drugs alongside kickbacks and a safety-reporting failure [10][12].<\/li>\n\n\n\n
  • Testosterone prescribing fell roughly a third to nearly two-thirds depending on the measure after a 2015 boxed warning, then rebounded past its prior peak after FDA removed that warning in February 2025 following the TRAVERSE trial [19][20][21].<\/li>\n\n\n\n
  • Compounded semaglutide revenue, built on a federal shortage listing rather than off-label promotion, ended on a regulatory calendar: FDA declared the shortage resolved on February 21, 2025, with wind-down deadlines that April and May [24][25].<\/li>\n\n\n\n
  • Not every off-label dispute ends badly for the manufacturer. Amarin’s Vascepa fight converted into a December 2019 label expansion and higher revenue guidance after the REDUCE-IT trial [30][34][35].<\/li>\n\n\n\n
  • Legal protection for truthful off-label speech is real but partial: a 2021 study found federal courts split almost evenly, 52 percent to 48 percent, on how far to extend Caronia’s holding [36].<\/li>\n<\/ul>\n\n\n\n

    References<\/h2>\n\n\n\n
      \n
    1. PBS FRONTLINE. (2020, January 24). Insys Executives Are Sentenced to Prison Time, Putting Opioid Makers On Notice.<\/em> https:\/\/www.pbs.org\/wgbh\/frontline\/article\/opioid-maker-insys-executives-sentenced-prison-subsys\/<\/li>\n\n\n\n
    2. Mintz. (2019). Insys Bankruptcy Filing Immediately After Global Settlement Triggers Powerful Remedies.<\/em> https:\/\/www.mintz.com\/insights-center\/viewpoints\/2406\/2019-06-insys-bankruptcy-filing-immediately-after-global-settlement<\/li>\n\n\n\n
    3. Ellis & Winters. D.A.R.E. to Market Off-Label Uses of Prescription Drugs? United States v. Caronia and the New Off-Label Landscape.<\/em> https:\/\/www.elliswinters.com\/blog\/<\/li>\n\n\n\n
    4. Ellis & Winters. United States v. Caronia and the New Off-Label Landscape.<\/em> (21 C.F.R. \u00a7\u00a7 201.5, 201.128 discussion.)<\/li>\n\n\n\n
    5. Bricker Graydon. (2012). GlaxoSmithKline LLC to Pay the Largest Health Care Fraud Settlement in U.S. History.<\/em> https:\/\/www.bricker.com\/insights\/publications\/<\/li>\n\n\n\n
    6. PBS FRONTLINE. (2020). Insys Executives Are Sentenced to Prison Time.<\/em> (Subsys approval and sales conduct detail.)<\/li>\n\n\n\n
    7. U.S. Department of Justice, District of Massachusetts. Founder and Former Chairman of the Board of Insys Therapeutics Sentenced to 66 Months in Prison.<\/em> https:\/\/www.justice.gov\/usao-ma\/pr\/founder-and-former-chairman-board-insys-therapeutics-sentenced-66-months-prison<\/li>\n\n\n\n
    8. ABC News. (2020, January 24). John Kapoor, Insys Therapeutics founder, sentenced for role in fraud, bribery scheme.<\/em> https:\/\/abcnews.com\/<\/li>\n\n\n\n
    9. U.S. Department of Justice, District of Massachusetts. (2025, September). U.S. Attorney’s Office Collects $48 Million Restitution Ordered Against Insys Executives.<\/em> https:\/\/www.justice.gov\/usao-ma\/pr\/us-attorneys-office-collects-48-million-restitution-ordered-against-insys-executives<\/li>\n\n\n\n
    10. JURIST. (2012). GlaxoSmithKline settles health care fraud case for $3 billion.<\/em> https:\/\/www.jurist.org\/news\/2012\/07\/glaxosmithkline-settles-health-care-fraud-case-for-3-billion<\/li>\n\n\n\n
    11. The Health Journals. (2012). GlaxoSmithKline to Pay $3 Billion in Colossal U.S. Health Care Fraud Settlement.<\/em><\/li>\n\n\n\n
    12. U.S. Department of Justice, Office of Public Affairs. (2012, July 2). Largest Health Care Fraud Settlement in U.S. History.<\/em><\/li>\n\n\n\n
    13. PharmaFile. (2012). GSK to pay ‘unprecedented’ $3 billion fraud charge.<\/em> https:\/\/pharmafile.com\/news\/173277\/gsk-pay-unprecedented-3-billion-fraud-charge<\/li>\n\n\n\n
    14. MBrady Law. GlaxoSmithKline Agrees to Largest Healthcare Fraud Settlement in History.<\/em><\/li>\n\n\n\n
    15. Lipocine Inc. (2014). Form 424B3, U.S. Securities and Exchange Commission. https:\/\/www.sec.gov\/<\/li>\n\n\n\n
    16. Drugwatch. Testosterone Lawsuits: Settlements, Verdicts, Dismissed Cases.<\/em> https:\/\/www.drugwatch.com\/testosterone\/lawsuits\/<\/li>\n\n\n\n
    17. American Patient Rights Association. Low-T Testosterone Heart Risk Lawsuit.<\/em><\/li>\n\n\n\n
    18. U.S. Food and Drug Administration. FDA issues class-wide labeling changes for testosterone products.<\/em> https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-issues-class-wide-labeling-changes-testosterone-products<\/li>\n\n\n\n
    19. Medical Dialogues. (2018). Fearing Side Effects: Sharp Decline in Testosterone Prescriptions,<\/em> citing Baillargeon et al., JAMA.<\/li>\n\n\n\n
    20. UPI. (2021, September 29). Testosterone therapy use, heart disease risk, study.<\/em> https:\/\/www.upi.com\/Health_News\/2021\/09\/29\/testosterone-therapy-use-heart-disease-risk-study\/3351632925835\/<\/li>\n\n\n\n
    21. Epic Research. (2026, July 29). After Nearly a Decade-Long Decrease, Testosterone Prescribing Rates Rising Again.<\/em> https:\/\/media.epic.com\/epicresearch\/wordpressmedia\/pdfs\/after-nearly-a-decade-long-decrease-testosterone-prescribing-rates-rising-again.pdf<\/li>\n\n\n\n
    22. Alston & Bird. (2025). FDA Resolves Semaglutide Shortage: Next Steps for Community Pharmacies, Telehealth Companies, and Other Providers.<\/em> https:\/\/www.alston.com\/en\/insights\/publications\/2025\/03\/fda-resolves-semaglutide-shortage<\/li>\n\n\n\n
    23. Pharmaceutical Technology. (2025, April). The GLP-1 drug shortage is over. What’s next for the compounders?<\/em> https:\/\/www.pharmaceutical-technology.com\/features\/the-glp-1-drug-shortage-is-over-whats-next-for-the-compounders\/<\/li>\n\n\n\n
    24. Burr & Forman LLP. (2025). The FDA Removes Semaglutide from the Drug Shortage List.<\/em><\/li>\n\n\n\n
    25. McDermott Will & Emery. (2025). Semaglutide Shortage Resolved.<\/em> https:\/\/www.mcdermottlaw.com\/insights\/semaglutide-shortage-resolved\/<\/li>\n\n\n\n
    26. ArentFox Schiff. (2025). FDA Announces End to Semaglutide Shortage, Impacting Compounders and Telehealth Providers.<\/em> https:\/\/www.afslaw.com\/perspectives\/alerts\/fda-announces-end-semaglutide-shortage-impacting-compounders-and-telehealth<\/li>\n\n\n\n
    27. Pharma Technology Focus. (2025, May). The GLP-1 drug shortage is over. What’s next for the compounders?<\/em><\/li>\n\n\n\n
    28. Pharmacy Times. (2026). FDA Moves to Permanently Close the Door on Compounded GLP-1s.<\/em> https:\/\/www.pharmacytimes.com\/view\/fda-moves-to-permanently-close-the-door-on-compounded-glp-1s<\/li>\n\n\n\n
    29. GLP-1 After Denial. (2026). Is Compounded Semaglutide Still Legal? (2026 Update).<\/em><\/li>\n\n\n\n
    30. Ropes & Gray. (2015). Amarin Court Holds Truthful Off-Label Speech Entitled to First Amendment Protection.<\/em> https:\/\/ropesgray.com\/en\/insights\/alerts\/2015\/08\/amarin-court-holds-truthful-off-label-speech-entitled-to-first-amendment-protection<\/li>\n\n\n\n
    31. Quimbee. United States v. Caronia, 703 F.3d 149 (2012).<\/em> https:\/\/www.quimbee.com\/cases\/united-states-v-caronia<\/li>\n\n\n\n
    32. LexBlog. (2015). Amarin Wins Injunction Against FDA Over Off-Label Marketing.<\/em><\/li>\n\n\n\n
    33. PharmaFile. (2016). Amarin wins case against FDA to promote Vascepa for off-label uses.<\/em> https:\/\/pharmafile.com\/news\/amarin-wins-case-against-fda-promote-vascepa-label-uses\/<\/li>\n\n\n\n
    34. Amarin Corporation plc. (2019). Form 10-K, U.S. Securities and Exchange Commission. https:\/\/www.sec.gov\/Archives\/edgar\/data\/897448\/000156459020006390\/amrn-10k_20191231.htm<\/li>\n\n\n\n
    35. Amarin Corporation plc. (2019, December 13). Amarin Receives FDA Approval of VASCEPA to Reduce Cardiovascular Risk<\/em> [Press release]. https:\/\/amarincorp.gcs-web.com\/node\/18451\/pdf<\/li>\n\n\n\n
    36. Richter, J. (2021). Prospects for Enforcing Prohibitions on Off-Label Drug Promotion after United States v. Caronia: An Analysis of Litigated Cases. Journal of Health Politics, Policy and Law, 46<\/em>(3), 487-504. https:\/\/pubmed.ncbi.nlm.nih.gov\/33647951\/<\/li>\n\n\n\n
    37. PMLive. [Caronia enforcement impact analysis].<\/em> https:\/\/pmlive.com\/<\/li>\n\n\n\n
    38. Arnold & Porter. (2025, January 13). FDA Finalizes Its SIUU Guidance: An Analysis of the Key Changes From the 2023 Draft Guidance.<\/em> https:\/\/www.arnoldporter.com\/en\/perspectives\/advisories\/2025\/01\/fda-finalizes-its-siuu-guidance<\/li>\n\n\n\n
    39. Troutman Pepper. (2025, January 22). FDA Finalizes Guidance on Communications of Scientific Information on Unapproved Uses.<\/em> https:\/\/www.troutman.com\/insights\/fda-finalizes-guidance-on-communications-regarding-unapproved-uses-of-medical-products\/<\/li>\n\n\n\n
    40. Mondaq. (2025). FDA Finalizes Guidance on Communication of Unapproved Uses of Approved or Cleared Medical Products.<\/em><\/li>\n\n\n\n
    41. Joint Commission Journal on Quality and Patient Safety. (2023). Longitudinal Patterns in Testosterone Prescribing After US FDA Safety Communication.<\/em> https:\/\/pubmed.ncbi.nlm.nih.gov\/37380503<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

      In April 2018, the Department of Justice intervened in five whistleblower lawsuits against Insys Therapeutics, alleging the company had built […]<\/p>\n","protected":false},"author":1,"featured_media":1232,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1231","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"modified_by":"DrugChatter","_links":{"self":[{"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/posts\/1231","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/comments?post=1231"}],"version-history":[{"count":1,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/posts\/1231\/revisions"}],"predecessor-version":[{"id":1233,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/posts\/1231\/revisions\/1233"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/media\/1232"}],"wp:attachment":[{"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/media?parent=1231"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/categories?post=1231"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/tags?post=1231"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}